| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Pathology [T. J. d. V., A. F., G. V., D. J. R., G. N. P. v. M.] and Surgery [T. W.], University Hospital, P. O. Box 9101, 6500 HB Nijmegen, the Netherlands
In recent years, it has become evident that T cells can recognize peptides of melanocytic lineage antigens such as gp100, MART-1, and tyrosinase at the tumor cell surface and can subsequently destroy these cells. It is thus feasible to develop immunotherapeutic approaches based on the melanocytic marker profiles of melanoma cells. One of the predictors of the success rate of such a treatment is the extent of positive (target) tumor cells within the lesions of the patient. First, we investigated the presence of these three proteins in 18 human melanoma cell lines using RT-PCR and immunohistochemistry. In 11 cell lines, mRNA and protein of all three markers could be detected; in one cell line, only two markers were present, and six melanoma cell lines showed no evidence for these markers. Secondly, we stained frozen sections of 105 human melanocytic lesions, 13 common nevocellular nevi, 13 atypical nevi, 13 early primary melanomas (Breslow <1.5 mm), 25 advanced primary melanomas (aPM; Breslow 
1.5 mm), and 41 melanoma metastases (MM) with antibodies against glycoprotein 100, melanoma antigen recognized by T cells, and tyrosinase. In addition, we used the 3,4-dihydroxyl-L-phenylalanine reaction to detect tyrosinase enzyme activity as a confirmation of the tyrosinase immunohistochemical results in a subset of the lesions. In the benign lesions, glycoprotein 100 was more prominently expressed in epidermal melanocytes, whereas melanoma antigen recognized by T cells was encountered in all or nearly all dermal melanocytes in all nevocellular nevi and atypical nevus lesions. Tyrosinase was found in a lower percentage of melanocytes, both in the epidermis and in the dermis within these lesions. With regard to heterogeneity of staining within the malignant lesions, we found that 54% (early primary melanomas), 48% (aPMs), and 56% (MM) of the lesions stained within the same staining category for all three proteins studied. Approximately 17% of the aPM and MM lesions did not show positive tumor cells for any of the three proteins. We conclude that a subgroup of patients with high expression should be selected for immunotherapeutic treatment approaches based on the presence of these proteins.
1 This work was supported by Grant NUKC 95-912 from the Dutch Cancer Society. The color illustration was sponsored by the EORTC Melanoma Cooperative Group.
2 To whom requests for reprints should be addressed. Fax: 31-24-3540520; E-mail: t.devries@pathol.azn.nl.
Received 2/ 6/97. Accepted 5/29/97.
This article has been cited by other articles:
|
|
 |
|
  C. Barrow, J. Browning, D. MacGregor, I. D. Davis, S. Sturrock, A. A. Jungbluth, and J. Cebon Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage Clin. Cancer Res., February 1, 2006; 12(3): 764 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Chianese-Bullock, J. Pressley, C. Garbee, S. Hibbitts, C. Murphy, G. Yamshchikov, G. R. Petroni, E. A. Bissonette, P. Y. Neese, W. W. Grosh, et al. MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma J. Immunol., March 1, 2005; 174(5): 3080 - 3086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. van Dinten, N. Pul, A. F. van Nieuwpoort, C. J. Out, M. J. Jager, and P. J. van den Elsen Uveal and Cutaneous Melanoma: Shared Expression Characteristics of Melanoma-Associated Antigens Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 24 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Meidenbauer, A. Zippelius, M. J. Pittet, M. Laumer, S. Vogl, J. Heymann, M. Rehli, B. Seliger, S. Schwarz, F.-A. L. Gal, et al. High Frequency of Functionally Active Melan-A-Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient Melanoma Cancer Res., September 1, 2004; 64(17): 6319 - 6326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Y. Wang, X. Chen, M. H. Manjili, E. Repasky, R. Henderson, and J. R. Subjeck Targeted Immunotherapy Using Reconstituted Chaperone Complexes of Heat Shock Protein 110 and Melanoma-associated Antigen gp100 Cancer Res., May 15, 2003; 63(10): 2553 - 2560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zhu, Z. Chen, X. Cheng, Z. Lin, J. Guo, Z. Jia, L. Zou, Z. Wang, Y. Hu, D. Wang, et al. Identification of HLA-A*0201-restricted Cytotoxic T Lymphocyte Epitope from TRAG-3 Antigen Clin. Cancer Res., May 1, 2003; 9(5): 1850 - 1857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Davids, S H Kidson, and G S Hanekom Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate Mol. Pathol., February 1, 2003; 56(1): 43 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Andersen, L. O. Pedersen, B. Capeller, E.-B. Brocker, J. C. Becker, and P. thor Straten Spontaneous Cytotoxic T-Cell Responses against Survivin-derived MHC Class I-restricted T-Cell Epitopes in Situ As Well As ex Vivo in Cancer Patients Cancer Res., August 1, 2001; 61(16): 5964 - 5968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Kurnick, T. Ramirez-Montagut, L. A. Boyle, D. M. Andrews, F. Pandolfi, P. J. Durda, D. Butera, I. S. Dunn, E. M. Benson, S. J. P. Gobin, et al. A Novel Autocrine Pathway of Tumor Escape from Immune Recognition: Melanoma Cell Lines Produce a Soluble Protein That Diminishes Expression of the Gene Encoding the Melanocyte Lineage Melan-A/MART-1 Antigen Through Down-Modulation of Its Promoter J. Immunol., August 1, 2001; 167(3): 1204 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Ohnmacht, E. Wang, S. Mocellin, A. Abati, A. Filie, P. Fetsch, A. I. Riker, U. S. Kammula, S. A. Rosenberg, and F. M. Marincola Short-Term Kinetics of Tumor Antigen Expression in Response to Vaccination J. Immunol., August 1, 2001; 167(3): 1809 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Koenig, J. Wojcieszyn, B. R. Weeks, and J. F. Modiano Expression of S100a, Vimentin, NSE, and Melan A/MART-1 in Seven Canine Melanoma Cell Lines and Twenty-nine Retrospective Cases of Canine Melanoma Vet. Pathol., July 1, 2001; 38(4): 427 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Rakhmilevich, M. Imboden, Z. Hao, M. D. Macklin, T. Roberts, K. M. Wright, M. R. Albertini, N.-S. Yang, and P. M. Sondel Effective Particle-mediated Vaccination against Mouse Melanoma by Coadministration of Plasmid DNA Encoding Gp100 and Granulocyte-Macrophage Colony-Stimulating Factor Clin. Cancer Res., April 1, 2001; 7(4): 952 - 961. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Berard, P. Blanco, J. Davoust, E.-M. Neidhart-Berard, M. Nouri-Shirazi, N. Taquet, D. Rimoldi, J. C. Cerottini, J. Banchereau, and A. K. Palucka Cross-Priming of Naive CD8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells J. Exp. Med., November 27, 2000; 192(11): 1535 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ramos-Vara, M. E. Beissenherz, M. A. Miller, G. C. Johnson, L. W. Pace, A. Fard, and S. J. Kottler Retrospective Study of 338 Canine Oral Melanomas with Clinical, Histologic, and Immunohistochemical Review of 129 Cases Vet. Pathol., November 1, 2000; 37(6): 597 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Panelli, M. P. Bettinotti, K. Lally, G. A. Ohnmacht, Y. Li, P. Robbins, A. Riker, S. A. Rosenberg, and F. M. Marincola A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12 J. Immunol., April 15, 2000; 164(8): 4382 - 4392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Colella, T. N.J. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard Self-Tolerance to the Murine Homologue of a Tyrosinase-derived Melanoma Antigen: Implications for Tumor Immunotherapy J. Exp. Med., April 3, 2000; 191(7): 1221 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. dos Santos, R. Torensma, T. J. de Vries, M. W. J. Schreurs, D. R. H. de Bruijn, E. Kater-Baats, D. J. Ruiter, G. J. Adema, G. N. P. van Muijen, and A. G. van Kessel Heterogeneous Expression of the SSX Cancer/Testis Antigens in Human Melanoma Lesions and Cell Lines Cancer Res., March 1, 2000; 60(6): 1654 - 1662. [Abstract] [Full Text]
|
|
|
|
|
|
F. Wang, E. Bade, C. Kuniyoshi, L. Spears, G. Jeffery, V. Marty, S. Groshen, and J. Weber Phase I Trial of a MART-1 Peptide Vaccine with Incomplete Freund's Adjuvant for Resected High-Risk Melanoma Clin. Cancer Res., October 1, 1999; 5(10): 2756 - 2765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Y. Cheung, N.-K. V. Cheung, R. A. Ghossein, J. M. Satagopan, S. Bhattacharya, and D. G. Coit Association between Molecular Detection of GAGE and Survival in Patients with Malignant Melanoma: A Retrospective Cohort Study Clin. Cancer Res., August 1, 1999; 5(8): 2042 - 2047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tanzarella, V. Russo, I. Lionello, P. Dalerba, D. Rigatti, C. Bordignon, and C. Traversari Identification of a Promiscuous T-Cell Epitope Encoded by Multiple Members of the MAGE Family Cancer Res., June 1, 1999; 59(11): 2668 - 2674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Palmieri, M. Strazzullo, P. A. Ascierto, S. M.R. Satriano, A. Daponte, and G. Castello Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression J. Clin. Oncol., January 1, 1999; 17(1): 304 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Tempero, M. L. VanLith, K. Morikane, G. J. Rowse, S. J. Gendler, and M. A. Hollingsworth CD4+ Lymphocytes Provide MUC1-Specific Tumor Immunity In Vivo That Is Undetectable In Vitro and Is Absent in MUC1 Transgenic Mice J. Immunol., November 15, 1998; 161(10): 5500 - 5506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Romero, P. Rod Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J.-L. Chen, D. Lienard, J.-C. Cerottini, and V. Cerundolo Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes J. Exp. Med., November 2, 1998; 188(9): 1641 - 1650. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
